CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer
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Cells were stained with CD24 and CD44 antibodies and the conjugated colors were detected by FACS. *, Mean ± SEM. #, the main population of H1419 is CD44-. The top 50 genes significantly up-regulated by docetaxel when compared with DMSO control in HCC1806. The top 50 genes significantly down-regulated by docetaxel when compared with DMSO control in HCC1806. Table shows the relationship between CD24 expression of tumors before/after neoadjuvant chemotherapy and cancer recurrence in nine TNBC patients. To further confirm the association between CD24 expression and breast cancer recurrence, we performed immunohistochemical staining of CD24 using tumors from an additional nine TNBC patients treated with taxane-based chemotherapy (neoadjuvant with or without postoperative adjuvant chemotherapy). The tumor samples from these patients were stained for CD24 by a laboratory researcher and read by a pathologist blinded for clinical outcomes of the patients. The results showed that all patients with high CD24 expression (2+ or 3+) before or after neoadjuvant treatment developed recurrent disease (mean time to recurrence 13.7 months) and all patients with low CD24 expression (0 or 1+) had no recurrent disease (mean follow up 47.5 months). Patient #5 whose tumor was 1+ before neoadjuvant treatment but increased to 2+ after taxane-based neoadjuvant treatment, later developed recurrent disease. were cultured on 40 µl matrigel for 7 days with the growth media containing 2% of matrigel. In (C) and (D), cells were treated with: 500 nM docetaxel (DTX) for 4 days ; 500 nM doxorubicin (DXR) for 4 days; 250 nM DTX for 2 days and then 250 nM DXR for 2 days; 250 nM DXR for 2 days and then 250 nM DTX for 2 days. In (E) and (F), cells were seeded in matrigel for 6 days in 96-Well plate and treated with the following reagents for 4 days: DMSO as control, 1 µl/well; docetaxel 0.4 µM; doxorubicin 40 nM; Bcl-2 inhibitor G3139 2 µM and ATM inhibitor KU60019 2 µM. (E) and (F) showed that single chemotherapy agent or inhibitor had limited effects on cell viabilities but the combinations of the two drugs and inhibitor dramatically increased the cell killing effects. The p-values between the compared groups were calculated with unpaired t-tests. *P < 0.05; **P < 0.01; ****P < 0.0001. All experiments were done in triplicate. Error bars represent SEM. Scale bar, 200 µm.
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